within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08E_NonSelectiveCalciumChannelBlockers.C08EA02_Bepridil;

model Bepridil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 1.944444444444445e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0003333333333333333,
    Tlag = 600,
    Vdp = 0.015,
    k12 = 1.7500000000000002e-05,
    k21 = 1.7500000000000002e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bepridil</td></tr><tr><td>ATC code:</td><td>C08EA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.1</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bepridil is a nonselective calcium channel blocker, formerly used for the management of angina pectoris and arrhythmias such as atrial fibrillation. Due to safety concerns, notably QT prolongation and risk of torsades de pointes, it is no longer approved or widely used in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C08EA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bepridil;
